Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Pazopanib is an angiogenesis inhibitor targeting VEGFR-1, -2, and -3; PDGFR- and -; and the receptor c-Kit, and is indicated for the treatment of subjects with advanced renal cell carcinoma (RCC) and advanced STS. For this orphan tumor, STS, PD-L1 targeting may be a promising strategy and favorable toxicity may …

KIT
angiogenesis inhibitor
cancer
metastatic soft tissue sarcoma
pazopanib
  • 1 views
  • 12 Feb, 2022
  • 1 location
TAEST16001 in the Treatment of Soft Tissue Sarcoma

This study is an open, single arm, dose increasing early clinical study, which is divided into two parts: "3 + 3" designed dose escalation study and extended group study. The purpose of this study is to evaluate the safety, tolerance, PK, PD characteristics, and preliminary efficacy of TAEST16001 immunotherapy in …

filgrastim
ny-eso-1
neutrophil count
cancer
doxorubicin
  • 0 views
  • 24 Nov, 2021
  • 1 location
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Background Researchers have found a new way to treat cancer using T cell therapy. The therapy used in this study is T Cell Receptor (TCR) Gene Therapy Targeting KK-LC-1, a cancer germline antigen that is expressed by certain cancers. This therapy is a type of treatment in which a participant …

  • 0 views
  • 13 Jun, 2022
  • 1 location
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Soft tissue sarcoma (STS) is a relatively rare type of malignant tumor with an incidence of 1-2/100000. For unresectable or widely disseminated advanced STS, a combined clinical trial is the best way to obtain evidence-based medical evidence. Anlotinib, a multi-target receptor tyrosine kinase inhibitor (TKI), is effective for various histological …

anlotinib
synovial sarcoma
malignant peripheral nerve sheath tumor
liposarcoma
epithelioid sarcoma
  • 0 views
  • 23 Nov, 2021
  • 1 location
Temozolomide for Injection Combined With Epirubicin in First-line Treatment of Leiomyosarcoma

This study is a single-center, prospective, one-arm clinical study, which is planned to be carried out in Cancer Hospital of Chinese Academy of Medical Sciences. The patients with locally advanced or metastatic leiomyosarcoma who are inoperable are enrolled, aiming at the effectiveness and safety of temozolomide for injection combined with …

leiomyosarcoma
cancer chemotherapy
neutrophil count
cancer
measurable disease
  • 0 views
  • 24 Mar, 2022
  • 1 location
Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

TCRT-ESO-A2 is an autologous cell therapy comprised of a subject's T cells stimulated ex vivo and transduced with a lentiviral vector encoding an affinity enhanced TCR targeting tumor-associated antigen NY-ESO-1. This study will investigate the safety, tolerability, activity, and pharmacokinetics/ pharmacodynamics of TCRT-ESO-A2 infusion. A maximum tolerated dose study of …

  • 0 views
  • 23 Mar, 2022
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.

systemic therapy
cancer
everolimus
international normalized ratio
direct bilirubin
  • 0 views
  • 26 Jan, 2022
  • 4 locations
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

>Synovial sarcoma Undifferentiated Sarcoma

cns tumor
Accepts healthy volunteers
solid tumor
cancer
  • 36 views
  • 14 Jun, 2022
  • 1 location
The Registry of Oncology Outcomes Associated With Testing and Treatment

This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and …

primary cancer
lab tests
diagnostic procedures
  • 0 views
  • 22 Oct, 2021
  • 1 location